KORU Medical Systems, Inc. (KRMD)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $160.05M
Last updated: Nov 17, 2026 at 4:10 PM ET
KORU Medical Systems, Inc. (KRMD) Statistics
KORU Medical Systems (KRMD) has a market cap of $160.05M. Its trailing P/E is 154.4x.
Total Valuation
| Market Cap | $160.05M |
|---|---|
| Latest price (Nov 17, 2026) | $3.49 |
Key Dates
The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 10, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 3.5x. Its year-end P/E ranged from 27.5x to 200.7x from 2016 to 2020.
| P/E Ratio | 154.4x |
|---|---|
| P/S Ratio | 3.5x |
| Forward P/S | 3.3x |
| P/OCF Ratio | 361.5x |
Price Statistics
The stock is down 19.21% over 52 weeks and trades 10.09% above its 50-day average.
| Beta (1Y) | 1.19 |
|---|---|
| 52-Week Change | -19.21% |
| 1-Month Change | +15.56% |
| 3-Month Change | +5.12% |
| 6-Month Change | -11.87% |
| 5-Year Change | +20.08% |
| 10-Year Change | +557.14% |
| Total Return (1Y) | -19.21% |
| Total Return (3Y CAGR) | +15.24% |
| Total Return (5Y CAGR) | +0.64% |
| Return vs SPY (1Y) | -33.48% |
| Max Drawdown (1Y) | -55.06% |
| Max Drawdown (3Y) | -57.96% |
| Sharpe Ratio (1Y) | -0.48 |
| Correlation with SPY (1Y) | 0.32 |
| 50-Day Average | $3.17 |
| 200-Day Average | $3.89 |
| 52-Week Range | $2.86 to $6.61 |
| RSI (14 Days) | 56.2 |
| Average Volume (20 Days) | 200.49K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.97x current liabilities.
| Current Ratio | 2.97x |
|---|---|
| Quick Ratio | 2.27x |
Returns and Efficiency
Return on equity is 0.00% over the last 12 months, against a 5-year average of -31.84%.
| Return on Equity (ROE) | 0.00% |
|---|---|
| Return on Assets (ROA) | 0.00% |
| Return on Capital Employed (ROCE) | 0.00% |
| ROE (5Y Average) | -31.84% |
| ROA (5Y Average) | -22.29% |
| ROIC (5Y Average) | -26.60% |
| Asset Turnover | 0.00x |
| Inventory Turnover | 0.00x |
| Receivables Turnover | 7.08x |
| Cash Conversion Cycle | 50285572 days |
Scores
KRMD has an Altman Z-Score of -1.02, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -1.02 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $46.27M over the last 12 months is up 18.43% from the 12 months before.
| Revenue | $46.27M |
|---|---|
| Revenue Growth (YoY) | +18.43% |
| Gross Profit | $29.24M |
| Operating Income | -$597.92K |
| Pretax Income | -$794.90K |
| Net Income | -$823.38K |
| EBITDA | $1.86K |
| EBIT | -$794.90K |
| Reported EPS (TTM) | $0.02 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 67.41% of the $28.78T in total assets.
| Cash and Equivalents | $7.36T |
|---|---|
| Working Capital | $13.35T |
| Shareholder Equity | $19.40T |
| Book Value Per Share | $415,029.47 |
| Tangible Book Value | $17.71T |
| Tangible Book Per Share | $378,999.94 |
| Total Assets | $28.78T |
| Total Liabilities | $9.39T |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.34M of capital spending, operating cash flow left -$900.55K of free cash flow.
| Operating Cash Flow | $442.70K |
|---|---|
| Capital Expenditures | $1.34M |
| Free Cash Flow | -$900.55K |
| FCF Per Share | -$0.02 |
| Depreciation and Amortization | $793.68K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -1.29%, against a 5-year average of -26.19%.
| Gross Margin | 63.20% |
|---|---|
| Operating Margin | -1.29% |
| Pretax Margin | -1.72% |
| Net Margin | -1.78% |
| EBITDA Margin | 0.00% |
| EBIT Margin | -1.72% |
| FCF Margin | -1.95% |
| Gross Margin (5Y Average) | 59.59% |
| Operating Margin (5Y Average) | -26.19% |
| Net Margin (5Y Average) | -24.62% |
Growth
Revenue grew 13.81% a year over 3 years.
| Revenue Growth (3Y CAGR) | +13.81% |
|---|---|
| Revenue Growth (5Y CAGR) | +11.21% |
| Book Value Per Share Growth (2Y CAGR) | -8.99% |
| Tangible Book Per Share Growth (2Y CAGR) | -9.14% |
Dividends and Yields
KRMD does not pay a dividend. Its free cash flow yield is -0.55%.
| Earnings Yield | 0.65% |
|---|---|
| FCF Yield | -0.55% |
| Shareholder Yield | 0.00% |
Peer Position
Against 5 similar companies, KRMD has the highest P/E.
P/E RatioPeer median 20.7x
P/S RatioPeer median 2.6x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +8.63%
| P/E Ratio | 154.4x vs 20.7x median |
|---|---|
| P/S Ratio | 3.5x vs 2.6x median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +18.43% vs +8.63% median |
Analyst Forecast
Consensus estimates put revenue growth at 16.68% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +16.68% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About KRMD
What is KRMD's market cap?
KORU Medical Systems has a market cap of $160.05M.
What is KRMD's P/E ratio?
KORU Medical Systems has a trailing P/E ratio of 154.4x.
How many shares of KRMD are outstanding?
KORU Medical Systems has 46.73M shares outstanding. The count is up 1.07% from a year earlier.
Does KRMD pay a dividend?
No. KORU Medical Systems does not pay a dividend.
KRMD pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors